NewAmsterdam Pharma (NASDAQ:NAMS) Issues Earnings Results, Beats Estimates By $0.06 EPS

NewAmsterdam Pharma (NASDAQ:NAMS) issued its quarterly earnings data on Thursday. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.06, FiscalAI reports. The company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $1.75 million. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 25.90%.

Here are the key takeaways from NewAmsterdam Pharma’s conference call:

• NewAmsterdam said it will hold a PREVAIL interim analysis in 4Q 2026, with results expected in 1Q 2027, after the trial reaches the minimum 2.5-year follow-up.
• Management said blinded PREVAIL data show the year one to year two MACE rate has been lower than expected, which they believe may reflect a treatment effect from obicetrapib.
• The company emphasized that PREVAIL is tracking similarly to BROADWAY, where obicetrapib previously showed a 21% reduction in exploratory MACE-4, and said this comparison supports the trial’s design and outlook.
• Executives said the interim analysis should come with substantially more events and greater power for MACE-4 than originally planned, while also noting the statistical penalty from the interim is minimal if the trial continues.
• They also highlighted potential broader benefits for obicetrapib beyond LDL-C, including large reductions in Lp(a), small LDL particles, and favorable renal signals, which they believe could strengthen the drug’s profile if PREVAIL is successful.

NewAmsterdam Pharma Stock Up 11.1%

NAMS traded up $3.88 during trading on Friday, hitting $38.73. The company’s stock had a trading volume of 4,805,879 shares, compared to its average volume of 1,041,712. NewAmsterdam Pharma has a one year low of $16.78 and a one year high of $42.00. The firm has a market cap of $4.45 billion, a PE ratio of -21.64 and a beta of 0.02. The business’s 50 day simple moving average is $31.77 and its 200-day simple moving average is $34.24.

Analyst Upgrades and Downgrades

NAMS has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday. Guggenheim increased their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Truist Financial began coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Finally, Needham & Company LLC increased their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $48.00.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 104,467 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $30.30, for a total value of $3,165,350.10. Following the transaction, the insider directly owned 69,302 shares in the company, valued at approximately $2,099,850.60. This trade represents a 60.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael H. Davidson sold 443,707 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the completion of the sale, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at approximately $5,790,288. This trade represents a 71.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 1,168,286 shares of company stock worth $38,211,967. Company insiders own 20.84% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

Hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN grew its stake in NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after acquiring an additional 300 shares in the last quarter. Empowered Funds LLC purchased a new position in NewAmsterdam Pharma during the fourth quarter valued at $85,000. Persistent Asset Partners Ltd purchased a new position in NewAmsterdam Pharma during the fourth quarter valued at $138,000. The Manufacturers Life Insurance Company grew its stake in NewAmsterdam Pharma by 5.3% during the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after acquiring an additional 544 shares in the last quarter. Finally, Guggenheim Capital LLC purchased a new position in NewAmsterdam Pharma during the fourth quarter valued at $224,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.